AnPac Bio-Medical Science Co., Ltd. (ANPC): Price and Financial Metrics
GET POWR RATINGS... FREE!
ANPC Stock Price Chart Interactive Chart >
ANPC Price/Volume Stats
| Current price | $0.28 | 52-week high | $4.52 |
| Prev. close | $0.29 | 52-week low | $0.20 |
| Day low | $0.27 | Volume | 301,249 |
| Day high | $0.29 | Avg. volume | 1,030,109 |
| 50-day MA | $0.30 | Dividend yield | N/A |
| 200-day MA | $1.18 | Market Cap | 5.39M |
AnPac Bio-Medical Science Co., Ltd. (ANPC) Company Bio
Anpac Bio-Medical Science Co., Ltd., a development-stage biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests to corporations and life insurance companies in the People's Republic of China and the United States. It also manufactures cancer differentiation analysis devices; and offers physical checkup package services. The company was founded in 2010 and is headquartered in Lishui, the People's Republic of China.
Latest ANPC News From Around the Web
Below are the latest news stories about AnPac Bio-Medical Science Co Ltd that investors may wish to consider to help them evaluate ANPC as an investment opportunity.
AnPac Bio Files CDA Device for Breakthrough Medical Device Designation Request with the FDAPHILADELPHIA, Feb. 03, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced today that it has filed for a Breakthrough device designation request for its cancer differentiation analysis (CDA) technology based medical device with the Food and Drug Administration (FDA) on February 1, 2022. AnPac Bio’s novel CDA techno |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWelcome back, trader! |
Leading US Market Analysis and Research Firm Ranked AnPac Bio Globally Number One in Multi-Cancer Screening and Detection Test VolumePHILADELPHIA, Jan. 25, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced today that Frost & Sullivan Company (“Sullivan”), a leading and well-known US market analysis and research firm has ranked AnPac Bio globally as number one in worldwide multiple cancer screening and detection volume in a recent research repo |
AnPac Bio receives Nasdaq notification regarding minimum market value (NASDAQ:ANPC)AnPac Bio-Medical Science (ANPC) has received a written notification from the Nasdaq that the Co |
G Medical, Reviva top healthcare gainers; OPKO Health, AnPac Bio-Medical among losersG Medical Innovations (GMVD) +18%. Reviva Pharmaceuticals (RVPH) +14%. OPKO Health (OPK) -20%. AnPac Bio-Medical Science (ANPC) -18%. |
ANPC Price Returns
| 1-mo | 0.54% |
| 3-mo | -36.36% |
| 6-mo | -77.05% |
| 1-year | -93.33% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -77.05% |
| 2021 | -76.98% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...